The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis
- 772 Downloads
Inflammation and neovascularization in vulnerable atherosclerotic plaques are key features for severe clinical events. Dynamic contrast-enhanced (DCE) MRI and FDG PET are two noninvasive imaging techniques capable of quantifying plaque neovascularization and inflammatory infiltrate, respectively. However, their mutual role in defining plaque vulnerability and their possible overlap has not been thoroughly investigated. We studied the relationship between DCE-MRI and 18F-FDG PET data from the carotid arteries of 40 subjects with coronary heart disease (CHD) or CHD risk equivalent, as a substudy of the dal-PLAQUE trial (NCT00655473).
The dal-PLAQUE trial was a multicenter study that evaluated dalcetrapib, a cholesteryl ester transfer protein modulator. Subjects underwent anatomical MRI, DCE-MRI and 18F-FDG PET. Only baseline imaging and biomarker data (before randomization) from dal-PLAQUE were used as part of this substudy. Our primary goal was to evaluate the relationship between DCE-MRI and 18F-FDG PET data. As secondary endpoints, we evaluated the relationship between (a) PET data and whole-vessel anatomical MRI data, and (b) DCE-MRI and matching anatomical MRI data. All correlations were estimated using a mixed linear model.
We found a significant inverse relationship between several perfusion indices by DCE-MRI and 18F-FDG uptake by PET. Regarding our secondary endpoints, there was a significant relationship between plaque burden measured by anatomical MRI with several perfusion indices by DCE-MRI and 18F-FDG uptake by PET. No relationship was found between plaque composition by anatomical MRI and DCE-MRI or 18F-FDG PET metrics.
In this study we observed a significant, weak inverse relationship between inflammation measured as 18F-FDG uptake by PET and plaque perfusion by DCE-MRI. Our findings suggest that there may be a complex relationship between plaque inflammation and microvascularization during the different stages of plaque development. 18F-FDG PET and DCE-MRI may have complementary roles in future clinical practice in identifying subjects at high risk of cardiovascular events.
KeywordsDCE-MRI PET/CT Atherosclerosis Inflammation Neovascularization
F. Hoffmann-La Roche Ltd funded the dal-PLAQUE study and provided third-party editorial support, through Prime Healthcare Ltd, for the preparation of the manuscript. C.C. acknowledges grant and research support from the National Institutes of Health and National Heart Lung and Blood Institute (NIH/NHLBI R01 HL071021, NIH/NHLBI R01 HL078667 and NIH/NCRR UL1RR029887).
Conflicts of interest
S.R., D.I.-G., A.M., D.R., J.B., E.M., J.G. and V.F. indicate that they have nothing to disclose. VM discloses that he receives consulting fees from Tursiop Inc. A.T. discloses that he has received honoraria from Roche, BMS and Novartis, and research grants from Merck, BMS, Genentech, GSK and VBL. M.W. discloses that he has received honoraria from Roche. D.K. is an employee of F. Hoffmann-La Roche Ltd. M.E.F. discloses that he has received honoraria from Roche and acted as a consultant to Genentech. J.H.F.R. discloses that he has received honoraria from Roche and is part-supported by the National Institute for Health Research Cambridge Biomedical Research Centre. Z.A.F. discloses that he has received research grants from Roche, GlaxoSmithKline, Merck, VBL Therapeutics, Novartis, Bristol-Myers Squibb, and Via Pharmaceuticals, and honoraria from Roche.
- 5.Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892–6.PubMedCrossRefGoogle Scholar
- 14.Fayad ZA, Mani V, Woodward M, Kallend D, Bansilal S, Pozza J, et al. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J. 2011;162:214–221.e2.PubMedCrossRefGoogle Scholar
- 18.Haacke EM, Brown RW, Thompson MR, Venkatesan R. Magnetic resonance imaging: physical principles and sequence design. New York: Wiley; 1999.Google Scholar
- 23.Hamlett A, Ryan L, Wolfinger R. On the use of PROC MIXED to estimate correlation in the presence of repeated measures. Proceedings of the Twenty-Ninth Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc.; 2004. paper 198-29.Google Scholar
- 24.Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993.Google Scholar
- 27.Cyran CC, Sourbron S, Bochmann K, Habs M, Pfefferkorn T, Rominger A, et al. Quantification of supra-aortic arterial wall inflammation in patients with arteritis using high resolution dynamic contrast-enhanced magnetic resonance imaging: initial results in correlation to [18F]-FDG PET/CT. Invest Radiol. 2011;46:594–9.PubMedCrossRefGoogle Scholar
- 29.Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem. 2002;277:6183–7.PubMedCrossRefGoogle Scholar
- 34.Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol. 2011;58:603–14.PubMedCrossRefGoogle Scholar